


Goat F(ab')₂ Anti-Mouse IgG_{2b}, Human ads

| Cat. No. | Format | Size |
|----------|--------------------------|---------|
| 1092-01 | Purified (UNLB) | 0.5 mg |
| 1092-02 | Fluorescein (FITC) | 0.5 mg |
| 1092-08 | Biotin (BIOT) | 0.5 mg |
| 1092-09 | R-phycoerythrin (PE) | 0.25 mg |
| 1092-30 | Alexa Fluor® 488 (AF488) | 0.5 mg |
| 1092-31 | Alexa Fluor® 647 (AF647) | 0.5 mg |



FLISA plate was coated with purified mouse IgG₁, IgG_{2a}, IgG_{2b}, IgG₃, IgM, and IgA. Immunoglobulins were detected with serially diluted Goat F(ab')₂ Anti-Mouse IgG_{2b}, Human ads-PE (SB Cat. No. 1092-09).

Description

| | |
|-------------------------|--|
| Specificity | Reacts with the heavy chain of mouse IgG _{2b} |
| Source | Pepsin digest of Goat Anti-Mouse IgG _{2b} , Human ads (SB Cat. No. 1090) |
| Cross Adsorption | Mouse IgG ₁ , IgG _{2a} , IgG ₃ , IgM, and IgA; human immunoglobulins and pooled sera; may react with immunoglobulins from other species |

Applications

Quality tested applications include –

ELISA
FLISA
FC¹⁻¹⁶

Other referenced applications include –

ICC¹⁷

Working Dilutions

| | | |
|---------------------------|--|--------------------------------|
| ELISA | BIOT conjugate | 1:5,000 – 1:10,000 |
| FLISA | FITC and AF488 conjugates | 1:200 – 1:400 |
| | PE and AF647 conjugates | ≤ 1 µg/mL |
| Flow Cytometry | FITC, BIOT, and AF488 conjugates | ≤ 1 µg/10 ⁶ cells |
| | PE conjugate | ≤ 0.2 µg/10 ⁶ cells |
| | AF647 conjugate | ≤ 0.1 µg/10 ⁶ cells |
| | For flow cytometry, the suggested use of these reagents is in a final volume of 100 µL | |
| Other Applications | Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need. | |

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC), Alexa Fluor® 488 (AF488), and Alexa Fluor® 647 (AF647) conjugates are supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.25 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

References

1. Schrader CE, Edelmann W, Kuchlerlapati R, Stavnezer J. Reduced isotype switching in splenic B cells from mice deficient in mismatch repair enzymes. *J Exp Med.* 1999;190:323-30. (FC)
2. Corver WE, Koopman LA, van der Aa J, Regensburg M, Fleuren GJ, Cornelisse CJ. Four-color multiparameter DNA flow cytometric method to study phenotypic intratumor heterogeneity in cervical cancer. *Cytometry.* 2000;39:96-107. (FC)
3. Stabel TJ, Bolin SR, Pesch BA, Rahner TE. A simple and rapid flow cytometric method for detection of porcine cell surface markers. *J Immunol Methods.* 2000;245:147-52. (FC)
4. Luby TM, Schrader CE, Stavnezer J, Selsing E. The μ switch region tandem repeats are important, but not required, for antibody class switch recombination. *J Exp Med.* 2001;193:159-68. (FC)
5. Husson H, Carideo EG, Cardoso AA, Lugli SM, Neuberg D, Munoz O, et al. MCP-1 modulates chemotaxis by follicular lymphoma cells. *Br J Haematol.* 2001;115:554-62. (FC)
6. Gelderman KA, Blok VT, Fleuren GJ, Gorter A. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. *Lab Invest.* 2002;82:483-93. (FC)
7. Dierssen JW, de Miranda NF, Mulder A, van Puijenbroek M, Verduyn W, Claas FH, et al. High-resolution analysis of HLA class I alterations in colorectal cancer. *BMC Cancer.* 2006;6:233. (FC)
8. Guikema JE, Linehan EK, Tsuchimoto D, Nakabeppu Y, Strauss PR, Stavnezer J, et al. APE1- and APE2-dependent DNA breaks in immunoglobulin class switch recombination. *J Exp Med.* 2007;204:3017-26. (FC)
9. Meurens F, Whale J, Brownlie R, Dybvig T, Thompson DR, Gerds V. Expression of mucosal chemokines TECK/CCL25 and MEC/CCL28 during fetal development of the ovine mucosal immune system. *Immunology.* 2007;120:544-55. (FC)
10. Delaleu N, Madureira AC, Immervoll H, Jonsson R. Inhibition of experimental Sjögren's syndrome through immunization with HSP60 and its peptide amino acids 437-460. *Arthritis Rheum.* 2008;58:2318-28. (FC)
11. Corver WE, Middeldorp A, ter Haar NT, Jordanova ES, van Puijenbroek M, van Eijk R, et al. Genome-wide allelic state analysis on flow-sorted tumor fractions provides an accurate measure of chromosomal aberrations. *Cancer Res.* 2008;68:10333-40. (FC)
12. Guikema JE, Schrader CE, Leus NG, Ucher A, Linehan EK, Werling U, et al. Reassessment of the role of Mut S homolog 5 in Ig class switch recombination shows lack of involvement in cis- and trans-switching. *J Immunol.* 2008;181:8450-9. (FC)
13. Delaleu N, Immervoll H, Cornelius J, Jonsson R. Biomarker profiles in serum and saliva of experimental Sjögren's syndrome: associations with specific autoimmune manifestations. *Arthritis Res Ther.* 2008;10:R22. (FC)
14. Guikema JE, Schrader CE, Brodsky MH, Linehan EK, Richards A, El Falaky N, et al. p53 represses class switch recombination to IgG2a through its antioxidant function. *J Immunol.* 2010;184:6177-87. (FC)
15. Stabel JR, Robbe-Austerman S. Early immune markers associated with Mycobacterium avium subsp. paratuberculosis infection in a neonatal calf model. *Clin Vaccine Immunol.* 2011;18:393-405. (FC)
16. Pasternak JA, Ng SH, Käser T, Meurens F, Wilson HL. Grouping pig-specific responses to mitogen with similar responder animals may facilitate the interpretation of results obtained in an out-bred animal model. *J Vaccines Vaccin.* 2014;5:5. (FC)
17. Peng SL, Moslehi J, Craft J. Roles of interferon- γ and interleukin-4 in murine lupus. *J Clin Invest.* 1997;99:1936-46. (ICC)

Alexa Fluor® 488, 647, and 555 are provided under an Intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.